PTGER2: Prostaglandin E2 receptor EP2 subtype
Receptor for prostaglandin E2 (PGE2).
- Drugs that act on it: 6
- Approved: 2
- In phases 1 to 3: 4
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on PTGER2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 6
Approved2
Phase 30
Phase 24
Phase 10
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Pfizer233%
- Ocuvex Therap117%
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Prostanoid EP2 receptor agonist.| AlprostadilBoxed warning | Approved | Pfizer | Small molecule | Agonist | 28 |
| Omidenepag isopropyl | Approved | Ocuvex Therap | Small molecule | Agonist | 0 |
| Evatanepag | Phase 2 | Pfizer | Small molecule | Agonist | 0 |
| Omidenepag | Phase 2 | — | Small molecule | Agonist | 0 |
| Simenepag isopropyl | Phase 2 | — | Small molecule | Agonist | 0 |
| Taprenepag isopropyl | Phase 2 | — | Small molecule | Agonist | 0 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Glaucoma
- 0.52
- Diabetic foot
- 0.39
- Cardiovascular disorder
- 0.37
- Patent ductus arteriosus
- 0.37
- Neurodegenerative disease
- 0.30
- Premature rupture of membranes
- 0.28
- Thyroid hormone resistance, generalized, autosomal dominant
- 0.27
- Fetal growth restriction
- 0.26
- Pain
- 0.26
Genes and related targets
Complexes and families that share a gene with this target- Genes
- PTGER2
- Related
- Prostaglandin E2 receptor
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1881, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P43116, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets